News Headlines Article

FDA OKs Merck hepatitis C drug, adding to patient choices
Washington Post

Patients with hepatitis C have yet another advanced treatment option, as the Food on Drug Administration has approved a new once-a-day pill developed by drugmaker Merck.

The FDA said Thursday Merck can begin marketing Zepatier (ZEP’-ah-teer), its new drug for patients with the liver-destroying virus. The combination pill includes the medications elbasvir and grazoprevir, which attack the virus in two different ways.

Merck hasn’t disclosed the list price for the drug, which requires a 12-week course of treatment. Insurers will demand significant discounts to cover the drug, in any case.